This site is intended only for healthcare professionals resident in the Republic of Ireland
In OCTAVE Induction 1 and 2, patients with moderately to severely active UC were randomised to receive XELJANZ 10 mg twice daily or placebo for 8 weeks. Patients who had a clinical response in the induction trials were enrolled into OCTAVE Sustain, and further randomised to receive either XELJANZ 5 mg twice daily maintenance therapy, XELJANZ 10 mg twice daily maintenance therapy or placebo for another 52 weeks.
Learn more about OCTAVE Induction and OCTAVE Sustain below.
XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.2
The recommended dose is 10 mg given orally twice daily for induction for 8 weeks. The recommended dose for maintenance treatment is 5 mg given orally twice daily.2
For further information on the recommended dosages for induction and maintenance treatment in UC patients, please refer to the Dosing page of this site and the XELJANZ Summary of Product Characteristics.
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
Learn more about the XELJANZ safety profile
Learn about dosing in UC
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023